← All trials
NCT04512716
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Aug 13, 2020
- Last posted
- Jun 8, 2021
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Actinium PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.